Adaptive Biotechnologies Business Summary

Adaptive Biotechnologies Corp (ADPT) operates a dual-segment business model centered on decoding the human adaptive immune system, generating revenue through its Minimal Residual Disease (MRD) and Immune Medicine divisions. The MRD segment, which accounted for approximately 86% of the company's $277 million in 2025 revenue, derives income from clinical diagnostic sales of its clonoSEQ assay and biopharmaceutical service contracts for monitoring treatment response. The Immune Medicine segment generates revenue through the immunoSEQ platform, providing high-throughput sequencing and data licensing to partners like Pfizer for drug discovery and clinical trial enrichment. Positioned against competitors such as 10x Genomics, Veracyte, and Guardant Health, Adaptive maintains a specialized market lead in T-cell and B-cell receptor (TCR/BCR) repertoire profiling, increasingly focusing on commercial diagnostic scaling to reach profitability. The company was co-founded in 2009 by brothers Chad Robins, who serves as Chairman and CEO, and Harlan Robins, PhD, the Chief Scientific Officer whose pioneering computational biology research at the Fred Hutchinson Cancer Research Center forms the basis of the company's technology. The leadership team includes President and COO Julie Rubinstein, who brings extensive commercial experience from Pfizer Oncology, and CFO Kyle Piskel, a CPA with a background at Expedia and Ernst & Young. Adaptive is governed by a board featuring Lead Independent Director Peter Neupert and clinical veterans like Robert Hershberg, MD, PhD. Historically supported by high-profile institutional investors including Viking Global Investors and Matrix Capital Management, the executive team is currently prioritized on executing a 2026 strategy focused on MRD volume growth and autoimmune diagnostic expansion.